补气健脾法治疗COPD急性加重期的理论与临床疗效研究
|
摘要
研究背景：
慢性阻塞性肺疾病(chronic obstructive pulmonary diseases,简称"COPD")是一种具有气流受限特征的肺部疾病,气流受限不完全可逆,呈进行性发展。由于其患病人数多,死亡率高,社会经济负担重,己成为一个重要的公共问题。COPD目前居全球死亡原因的第4位,世界银行/世界卫生组织公布,至2020年COPD将位居世界疾病经济负担的第5位。在我国,COPD同样是严重危害人民身体健康的重要慢性呼吸系统疾病。COPD病程可分为急性加重期与稳定期。
目的：
系统阐述总结仲景治肺理论及西医治疗,评价麦门冬汤治疗肺脾气虚型慢性阻塞性肺疾病急性加重期的临床疗效及安全性,为慢性阻塞性肺疾病急性加重期的中医药规范化治疗提供依据,从而提高中医药防治慢性阻塞性肺疾病的水平。
方法：
通过查阅大量文献,阐述《金匮要略》中治疗肺系疾病的理论研究；阐述西医病因、发病机理,以及临床诊治特点；并分别为之建立相关资料库以供后来者进行查阅使用。在临床研究上,将入选的41例肺脾气虚型慢性阻塞性肺疾病急性加重期患者按随机化原则分治疗组和对照组。其中对照组予西医常规治疗方案治疗；治疗组在西医常规治疗方案的基础上联用麦门冬汤治疗,观察两组患者治疗前后主要临床疗效及临床症状等改善情况。
结果：
1.临床疗效：经Ridit分析,P<0.05,说明治疗组与对照组疗效差异有显著性；经X2分析,P<0.05,故两组在显控率上有显著差异。治疗组总有效率为100.00%,对照组总有效率为95.24%,经X2分析,P>0.05,故两组在总有效率上无显著性差异。
2.症状体征：两组治疗后各项主要症状及体征相比较,具有显著性差异(P<0.05),治疗组的治疗方案在改善患者的症状与体征方面优于对照组。
3.3.肺功能方面：经过治疗,在改善用力肺活量占预计值的比例Fvc/pre%),一秒量占预计值比例(Fevl/pre%),两组治疗后组间比较,治疗组优于对照组,有显著性差异(P<0.05.)故治疗改善肺功能方面优于对照组。
结论：
麦门冬汤治疗肺脾气虚型慢性阻塞性肺疾病急性加重期的有明确的临床疗效,能很好的改善患者的症状及肺功能作用。提高生存质量。
Background:
Chronic obstructive pulmonary disease is a kind of chronic disease, which is characteristic by airflow limitation and showed a progressive development. As the number of patients, high mortality, social and economic burden, has become an important public issue. The death of COPD now ranks in the forth of the world; the World Bank/World Health Organization announced, in the2020year, the world economic burden of disease of COPD will be in the fifth. In China, COPD is also important chronic respiratory diseases that seriously endanger people's health. COPD can be divided into acute exacerbation and stable stages.
Objective:
Systems summarize the Zhongjing Zhifei theory and Western medicine treatment, evaluation of the clinical efficacy and safety of Ophiopogon Decoction to hronic obstructive pulmonary disease with acute exacerbation of lung spleen deficiency.
So, standardized treatment of the chronic obstructive pulmonary disease with acute exacerbations of Traditional Chinese Medicine. thereby increasing the level of prevention of chronic obstructive pulmonary disease.
Methods:
Through extensive literature, expounded the Theory of the Zhong jing's "Golden Chamber" in treating lung diseases; elaborate Western etiology, pathogenesis, and clinical diagnostic and therapeutic features. Respectively. In clinical studies, Randomized controlled by a simple method,41patients were divided into control group and treatment group, Control group with conventional Western treatment; treatment group on the basis of conventional Western treatment and Ophiopogon Decoction, observed two groups of clinical efficacy and improvement in clinical symptoms before and after the treatment.
Results:
(1) The clinical efficacy:Trough Ridit analysis, In the two groups there was very different significant rate of efficiency. by X2analysis, so the two groups in the display and control rates were significantly different. But, there was no difference of the two groups in the total efficiency.
(2) signs and symptoms:the control group is better than the treatment group of the improvement of the Symptoms.
(3) Treatment groups in lung function improvement is better than the control group.
Conclusion:
Ophiopogon Decoction is a safe and effective method, can improve patient symptoms. Improve the quality of life.
慢性阻塞性肺疾病(chronic obstructive pulmonary diseases,简称"COPD")是一种具有气流受限特征的肺部疾病,气流受限不完全可逆,呈进行性发展。由于其患病人数多,死亡率高,社会经济负担重,己成为一个重要的公共问题。COPD目前居全球死亡原因的第4位,世界银行/世界卫生组织公布,至2020年COPD将位居世界疾病经济负担的第5位。在我国,COPD同样是严重危害人民身体健康的重要慢性呼吸系统疾病。COPD病程可分为急性加重期与稳定期。
目的：
系统阐述总结仲景治肺理论及西医治疗,评价麦门冬汤治疗肺脾气虚型慢性阻塞性肺疾病急性加重期的临床疗效及安全性,为慢性阻塞性肺疾病急性加重期的中医药规范化治疗提供依据,从而提高中医药防治慢性阻塞性肺疾病的水平。
方法：
通过查阅大量文献,阐述《金匮要略》中治疗肺系疾病的理论研究；阐述西医病因、发病机理,以及临床诊治特点；并分别为之建立相关资料库以供后来者进行查阅使用。在临床研究上,将入选的41例肺脾气虚型慢性阻塞性肺疾病急性加重期患者按随机化原则分治疗组和对照组。其中对照组予西医常规治疗方案治疗；治疗组在西医常规治疗方案的基础上联用麦门冬汤治疗,观察两组患者治疗前后主要临床疗效及临床症状等改善情况。
结果：
1.临床疗效：经Ridit分析,P<0.05,说明治疗组与对照组疗效差异有显著性；经X2分析,P<0.05,故两组在显控率上有显著差异。治疗组总有效率为100.00%,对照组总有效率为95.24%,经X2分析,P>0.05,故两组在总有效率上无显著性差异。
2.症状体征：两组治疗后各项主要症状及体征相比较,具有显著性差异(P<0.05),治疗组的治疗方案在改善患者的症状与体征方面优于对照组。
3.3.肺功能方面：经过治疗,在改善用力肺活量占预计值的比例Fvc/pre%),一秒量占预计值比例(Fevl/pre%),两组治疗后组间比较,治疗组优于对照组,有显著性差异(P<0.05.)故治疗改善肺功能方面优于对照组。
结论：
麦门冬汤治疗肺脾气虚型慢性阻塞性肺疾病急性加重期的有明确的临床疗效,能很好的改善患者的症状及肺功能作用。提高生存质量。
Background:
Chronic obstructive pulmonary disease is a kind of chronic disease, which is characteristic by airflow limitation and showed a progressive development. As the number of patients, high mortality, social and economic burden, has become an important public issue. The death of COPD now ranks in the forth of the world; the World Bank/World Health Organization announced, in the2020year, the world economic burden of disease of COPD will be in the fifth. In China, COPD is also important chronic respiratory diseases that seriously endanger people's health. COPD can be divided into acute exacerbation and stable stages.
Objective:
Systems summarize the Zhongjing Zhifei theory and Western medicine treatment, evaluation of the clinical efficacy and safety of Ophiopogon Decoction to hronic obstructive pulmonary disease with acute exacerbation of lung spleen deficiency.
So, standardized treatment of the chronic obstructive pulmonary disease with acute exacerbations of Traditional Chinese Medicine. thereby increasing the level of prevention of chronic obstructive pulmonary disease.
Methods:
Through extensive literature, expounded the Theory of the Zhong jing's "Golden Chamber" in treating lung diseases; elaborate Western etiology, pathogenesis, and clinical diagnostic and therapeutic features. Respectively. In clinical studies, Randomized controlled by a simple method,41patients were divided into control group and treatment group, Control group with conventional Western treatment; treatment group on the basis of conventional Western treatment and Ophiopogon Decoction, observed two groups of clinical efficacy and improvement in clinical symptoms before and after the treatment.
Results:
(1) The clinical efficacy:Trough Ridit analysis, In the two groups there was very different significant rate of efficiency. by X2analysis, so the two groups in the display and control rates were significantly different. But, there was no difference of the two groups in the total efficiency.
(2) signs and symptoms:the control group is better than the treatment group of the improvement of the Symptoms.
(3) Treatment groups in lung function improvement is better than the control group.
Conclusion:
Ophiopogon Decoction is a safe and effective method, can improve patient symptoms. Improve the quality of life.
引文
[1]汉·张仲景(述),钱超尘等(整理).伤寒论.北京：人民卫生出版社,2005：13.
[2]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：21.
[3]田代华(整理).灵枢经.北京：人民卫生出版社,2005：75.
[4]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：45.
[5]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：17.
[6]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：87.
[7]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：11.
[8]田代华(整理).灵枢经.北京：人民卫生出版社,2005：134.
[9]秦越人(编撰).难经.北京：科学技术文献出版社,1999：23.
[10]秦越人(编撰).难经.北京：科学技术文献出版社,1999：16.
[11]秦越入(编撰)难经.北京：科学技术文献出版社,1999：22.
[12]秦越人(编撰).难经.北京：科学技术文献出版社,1999：27.
[13]田代华(整理).灵枢经。北京：人民卫生出版社,2005：12.
[14]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：75.
[15]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：114.
[16]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：74.
[17]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：79.
[18]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：49.
[19]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：94.
[20]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：48.
[21]秦越人(编撰)难经.北京：科学技术文献出版社,1999：10.
[22]田代华(整理).黄帝内经素问.北京：人民卫生出版社,200s：183.
[23]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：46.
[24]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：47.
f25]秦越人(编撰1难经.北京：科学技术文献出版社,1999：36.
[26]秦越人(编撰1难经.北京：科学技术文献出版社,1999：7.
[27]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：12.
[28]田代华(整理).黄帝内经素问.北京：人民卫生出版社,200s：13.
[29]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：8.
[30]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：27.
[31]汉·张仲景(撰),何任等(整理)金匿要略.北京：人民卫生出版社,2005：54.
[32]清·唐宗海(著),魏武英等(整理)血证论.北京：人民卫生出版社,2005：139.
[33]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：44.
[34]明·赵以德.金匮方论衍义.北京：中国中医药出版社,1993：106.
[35]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：4.
[36]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：26.
[37]汉.张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：27.
[38]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：28.
[39]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：22.
[40]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：31.
[41]奚肇庆.试论《金匮要略》胸痹与肺的证治.南京中医药大学学报：1995,11(3)：6.
[421汉·张仲景(撰)’何任等(整理).金匮要略.北京：人民卫生出版社,2005：48.
[43]韩春生,张洪春.《金匮要略》肺病诸方探要.国医论坛：1996,11(1)：3.
[441汉·张仲景(撰),何任等(整理).金匮要略.北京：人民卫生出版社,2005：51.
[45]黄树曾.金匮要略释义.北京：人民卫生出版社,1960：166.
[46]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版桂,2005：7.
[47]汉·张仲景(撰),何任等(整理)金匮要略.北京：入民卫生出版社,2005：8.
[48]汉·张仲景(撰),何任等(整理)金匮要咯北京：人民卫生出版社,2005：19.
[49]汉·张仲景(撰)’何任等(整理)金匮要略.北京：人民卫生出版社,2005：21.
[50]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：55.
[51]明·张介宾类经.上海：上海古籍出版社,1997：776-21.
[52]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：62.
[53]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：41.
[54]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：69.
[55]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：42.
[56]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：56.
[57]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：70.
[58]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：78.
[59]清·柯琴(编撰)伤寒来苏集·伤寒论翼.上海：上海科学技术出版社,1,59：27.
[60]明·汪绮石(撰),谭克陶等(整理).理虚元鉴.北京：人民卫生出版社,2005：15.
[61]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：23.
[62]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：29.
[63]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：12.
[64]清·张锡纯.医学衷中参西录.石家庄：河北人民出版社,1974：245.
[65]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：79.
[66]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：145.
[67]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：83.
[68]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：45.
[69]清·李踅.金匮要略广注.北京：中国中医药出版社,1992：103.
[70]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：86.
[71]汉·张仲景(撰),何任等(整理)金匮要略。北京：人民卫生出版社,2005：46.
[72]清·程杏轩.医述.合肥：安徽科学技术出版社,1990：794.
[73]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：3.
[74]清·唐宗海.中西汇通医书五种.上海千顷堂书局,1937：156.
[75]清·唐宗海(撰),王咪咪等(主编).唐容川医学全书.北京：中国中医药出版社,1999：209.
[76]清·喻昌(著),徐复霖(点校).医门法律.上海：上海科学技术出版社,1983：269.
[77]清·周岩.本草恩辨录.北京：人民卫生出版社,1963：16.
[78]清·吴谦等(编著),闫志安等(校注).医宗金鉴.北京：中国中医药出版社,1994：6.
[79]清·叶天士(著),潘华信等(主编).叶天士医案大全.上海：上海中医药大学出版社,1994：56.
[80]清·柯琴(编撰).伤寒来苏集·伤寒附翼.上海：上海科学技术出版社,1959： 9.
[81]柴可夫(编著),《金匮要略》理法方药研究,上海：上海中医药大学出版社,2002：190.
[82]清·黄官绣.本革求真.北京：人民卫生出版社,1987：83.
[83]明·李时珍.本草纲目.北京：人民卫生出版社,2004：1008.
[84]魏·吴普等(述),清-孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：92.
[85]魏.吴普等(述),渣·孙星衍,孙冯翼(辑)。神农本草经。北京：科学技术文献出版社,1999：57.
[86]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005：161.
[87]粱·陶弘景(集).名医别录(辑校本)。北京：人民卫生出版社,1986：104.
[88]魏·吴普等(述),清·孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：18.
[89]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005：21.
[90]清·赵学敏.本草纲目拾遗.北京：中国中医药出版社,1998：332.
[91]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 9.
[92]明·李时珍.本草纲目.北京：人民卫生出版社,2004：1268.
[93]魏·吴普等(述),清·孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：58.
[94]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 189.
[95]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：5.
[96]田代华(整理).灵枢经.北京：人民卫生出版社,2005：96.
[97]清·柯琴(著).伤寒来苏集·伤寒附翼.上海：上海科学技术出版社,1959： 1.
[98]清·张山雷.张山雷医集.北京：人民卫生出版社,1995：234.
[99]汉·张仲景(撰),何任等(整理)金匿要嗡北京：人民卫生出版社,2005：21.
[100]清·张璐.张氏医通。北京：中国中医药出版社,1995：74.
[101]明·李时珍本草纲目.北京：人民卫生出版社,2004：818.
[102]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 200.
[103]明·李时珍本草纲目.北京：人民卫生出版社,2004：1239。
[104]中华医学会呼吸病学分会.《慢性阻塞性肺疾病诊治指南(2007年修订版)》中华内科杂志,2007,46(3)：254。
[105]Zhong W ang C, Ran P, et a.l Prevalence of chron icob structive pulmonary disease in China:a large, population-based survey[J]. Am J Resp ir CarM ed,2007,176:753-760
[106]HalbertR J, Isonaka S, George D, IqbalA. Interpret ing COPD prevalen ceestimates:what what is the true burden of disease[J] Chest 2003,123:1684-1692.
[107]Preseott E:Vestbo J. Socioeconomic status and chronic obstructv epulmonary disease Thorax,1999,54:737—741.
[108]Anthonisen NR:Connett JE:Murray RP. Smoking and lung function of Lung Health Study participants after 11 years.Am J ResPir Crit Care Med,2002,166:675-679.
[109]冉丕鑫,王辰,姚婉贞,等.我国部分农村地区40岁以上女性慢性阻塞性肺疾病危险因素分析中华内科杂志,2006,45(12)：974-979.
[110]张明泳,刁玉荃.慢性阻塞性肺疾病危险因素的调查.齐鲁医学杂志,2007,22(5)：441-444
[111]Bosse Y. Genetics of chronic obstructive pulmonary disease:a succinct review, future succinct review, future avenues and prospective clinical applications [J]. Pharmacogenomics, 2009; 10(4):655-67.
[112]Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis,2007; 2 (4):541-50.
[113]Rennard SI. COPD:Overview of definitions, Epidemiology and factors influencing its deve lopment. Chest,1998,113:235-241.
[114]Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency[J]. Scand J Clin Lab Invest,1967;19(3):205-8.
[115]Hersh CP, Pillai SG, Zhu G, et al. Multistudy fine mapping of chromosome 2q identifies 2q identifies XRCC5 as a COPD Susceptibility Gene[J]. Am J Respir Crit Care Med,2010; 182(5):605-13.
[116]钱小顺,朱元任,许文兵,等.127例肺部真菌感染的临床分析[J].中华结核和呼吸杂志,2000；23(7)：417-419.
[117]赵玲珑,肖玉艳.慢性阻塞性肺疾病发病因素研究进展[J].广东医学,2006,27(9)：42-43.
[118]程显声,武阳本,李景周等.吸烟者慢性阻塞性肺病易患因素的研究[J].中华结核和呼吸杂志1999；22：602-604.
[119]谢高强,程显声,徐希胜,等.慢性支气管炎患者慢性阻塞性肺疾病发病影响因素的研究.中华医学杂志,2001,81(22)：1356-1359.
[120]王红阳,赵雪峰,李球兵,等COPD及其吸烟患者IL-8、TNF-a、hsCRP的检测及意义.山东医药,2007,47(32)：42-44.
[121]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版).中 华结核和呼吸杂志,2007：30(1)：8-17.
[122]H arik-Khan R I, Fleg J L, W ise R A. Body mass index and the risk of COPD[J]. Chest,2002, 121(2):370-376.
[123]邝锦辉.吸烟与慢性阻塞性肺气肿的发病机理.国外医学呼吸系统分册,2000；20(1)：33-36.
[124]Chaudhuri N, Dower SK, Whyte MK, et al. Toll-like receptors and chnic Lung disease. Clin Sci(Lond),2005:109:125-133.
[125]Turino GM. Emphysema in COPD:consequence and eanses. Th orax.2006; 61:1031.1032.
[126]蔡柏蔷.慢性阻塞性肺部疾病发病机制的新进展.中华内科杂志,2000；39(3)：204-206.
[127]蔡柏蔷.呼吸内科学,北京：中国协和医科大学出版社,2005；5：325-346.
[128]MaestrelliP, Paskae, SaeRa M, et al. Decreased hacm oxygenase-land Inereased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J,2003; 21:971-976.
[129]王晓园,许西琳,刘冬,等.慢性阻塞性肺疾病患者血清Fas/A pol及TNF-a与细胞凋亡的相关性研究.临床肺科杂志2008,13(10)：1294-1295.
[130]王金泉.对慢性阻塞性肺疾病(COPD)的认识[J].中国中医药现代远程教育.2010,82(2)：136.
[131]W alter RE, W ilk JB, Larson MG, et al System ic inflammation and COPD:the Fram ing ham Heart Study [J].Chest,2008,133 (1):19-25.
[132]Pierce R. Spirom etry:an essential clinicalm easurement[J]. Aust Fam Physician,2005, 34(7):535-539.
[133]张利华,王云华COPD肺功能影像学诊断研究进展[J]长治医学院学报,2010,23(3)：237-240.
[134]熊玉干,陈蕾.呼吸肌功能锻炼对老年慢性阻塞性肺疾病患者运动耐力的影响[J].淮海医药,2006,24(6)：514-515.
[135]胥杰孙永昌COPD急性加重的治疗原则[J].临床药物治疗杂志2011,9(6)：45-47.
[136]黄维建COPD急性加重期综合治疗探讨[J].实用心脑肺血管病杂志,2010,18(7)：1012-1013.
[137]白春学.慢性阻塞性肺疾病急性加重期的综合治疗[J].中国临床医学,2003,10(4)：439-441.
[138]蔡柏蔷.科学认识、重视防治、勇于探索—评析国内外慢性阻塞性肺疾病诊断和治疗新指南[J].内科理论与实践,2007,2：287-291.
[139]Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacer bations and airflow in patients with COPD[J]. Eur Respir J,2006; 27 (3):547-55.
[140]Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J]. N Engl J Med,2007; 356(8):775-89.
[141]Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmaco-therapy On rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study[J]. Am J Respir Crit Care Med,2008;178(4):332-8.
[142]Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronicobstructive in chronicobstructive pulmonary disease[J]. N Engl J Med,2008; 359 (15):1543-54.
[143]Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pul-monary disease (UPLIFT):a prespecif ied subgroup subg roup analysis of a randomised controlled clinical trial [J]. Lancet,2009; 374; (9696):1171-8.
[144]Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies [J]. Int J Chron Obstruct Pulmon Dis TORCH and UPLIFT 2009; 4(1):185-201.
[145]LIPWORTH B J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmo ary disease [J].Lancet,2005,365:167-175.
[146]李时珍、许仁勇、陈青妹等.非诺特罗和异丙托澳钱雾化吸入治疗稳定期慢性阻塞性肺病[J].蚌埠医学院学报,2001；26(3)：224-225.
[147]BRUSASCO V, HODDER R, M IRAV ITLLES M, et al.Health outcomes following treatment for six months with once daily tiotrop iura compared with twice daily salm eterol in patients with COPD[J]. Thorax,2003,58:399-404
[148]李周平.慢性阻塞性肺疾病治疗进展[J].实用医院临床杂志2007,1(4)：404-26.
[149]李国平.慢性阻塞性肺疾病治疗进展[J].实用医院临床杂志,2007,1(4)：25-26.
[150]楼英彪、应延风.缓释茶碱对中重度慢性阻塞性肺疾病生存质量影响[J].中华实用中西医杂志,2003：3(16)：1549-1552.
[151]施焕中.慢性阻塞性肺疾病[M].北京：人民卫生出版社,2006：79-84.
[152]周伟雄.普米克令舒和博利康尼联合雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].实用临床医学,2006,7(9)：54-55.
[153]Zafarullah M, Li WQ, Sylvester J, et al. Molecular mechanisms of N-acetylcysteine actions [J].Cell Mol Life Sci,2003,60:6-20.
[154]Massaro GD.Massaro D. Retinotic acid treament partially rescues failed septation in rats failed septation in rats and in mice[J]. Am J Physiol Lung Cell Mol Physiol,2000,278:955-960.
[155]Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD[J].Eur Respir J,2006,27(3):547-55.
[156]Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356(8):775-89.
[157]Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmaco-therapy on rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study[J].Am J Respir Crit Care Med,2008; 178(4):332-8.
[158]Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med,2008; 359
[159]Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pul-monary dis ease(UPLIFT):a prespecified subgroup analysis of a randomised contr olled clinical trial[J]. Lancet,2009; 374(9696):1171-8
[160]Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients:less ons from the TORCH and UPLIFT studies [J]. Int J Chron Obstruct Pulmon Dis,2009; 4(1); 185-201.
[161]Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary [J]. Am J Respir Crit Care Med,2007; 176(6):532-55.
[162]丁进,应延风,王永兴.茶碱对中重度慢性阻塞性肺疾病稳定期肺功能和症状的影响[J].现代中西医结合杂志,2004：13(2)：147-8.
[163]Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination the rapy in the treatment of COPD[J]. Chest,2001; 119(6):1661-70.
[164]Cosio BG, Soriano JB. Theophyl line again Reasons for believi[J].2009; 33(5):1010-7.
[165]Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory the anti-inflammatory effects of steroids during exacerbations of COPD[J]. Thorax,2009; 64(5):424-9.
[166]Alifano M, Cuvelier A, Delage A. Treatment of COPD:from pharmao logical to instrumental logical to instrumental therapies[J].Eur Respir Rev,2010; 19(115)-
[167]Kawayama T, Hoshino T, Ichiki M, et al. Effect of add-on therapy of tiotropium in COPD (?)ated with theophylline[J]. Int J Chron Obstruct Pulmon Dis,2008; 3(1):137-47.
[168]Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dexamethasone of cytokine dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease[J]. Am J Respir OritCare Med,2003,167 (1):24-31.
[169]唐继红,顾宗元,王磊,等.皮质激素水平和全身性皮质激素在稳定期慢性阻塞性肺疾病中的应用[J].中华现代内科学杂志,2007,32(4)：389-391.
[170]Zheng JP, Kang J, Huang SG, et al. Effect of Carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a ran-domised placebo-controlled study J). Lancet,2008; 371
[171]陆再英,钟南山.内科学[M].北京：人民卫生出版社,2008：132-138
[172]Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD;a randomized placebo-controlled randomized placebo-controlled study (J).Chest,2009; 136(2):381-6.
[173]Campos M A, Wanner A. The rationale for pharmacologic therapy in stable chronic obstructivepulmonary disease[J]. Am J Med Sci,2005,329(4):181-189.
[174]陈新谦,金有豫,汤光.新编药物学[M].16版.北京：人民卫生出社,2007：213-219.
[175]马国尔,郑金旭.中性粒细胞弹性蛋白酶抑制剂研究现状[J].国际呼吸杂志,2006,26(4)：257-259.
[176]谭群友,龚太乾,王如文,蒋耀光.慢性阻塞性肺疾病的外科进展[J]临床外科杂志,2004：12(5)：310.
[177]0ey IF;Morgan MD; Singh SJ. The long term health status improv ements seen after lung volume reduetion surgery[J]. Eur J Cardiothorac Surg;2003;24 (4):6142619.
[178]刘锦铭,杨文兰,姜格宁；等.肺移植对5例慢性阻塞性肺疾病患者肺功能的影响.中华结核和呼吸吸杂志；2005,28(8)：509-512.
[179]Global Strategy for the Diagnosis, Management, and Preventionof Chronic obstruetive Pulmonary Disease(2006).2006 Global Initative for Chronic obstruetive Lung Disease.
[180]杨悦,许少华.78例重度COPD患者对COPD的认知及治疗现状[J].医学临床研究,2006,23(6)
[181]Geddes EL, ReidWD, Crowe J, et a 1. Inspiratory muscle training in adults with obstruc tive pulm on ary disease an update of a system at ic review[J]. RespirMed,2005,99(11): 1140-1158.
[182]Alneriean thoracic soeiety. Pulmonary rehabilitation,1999. Am J ResPir Crit Care Med, 1999; 159:1666-1682.
[183]黎东明,林志雄.慢性阻塞性肺疾病患者心理状况及影响因素分析[J].海预防医学杂志,2005,17(1)：5-7.
[184]Houghton L. Thenutritional man agement of weight loss in COPD[J]. Best Practice, 2008(15),16-17.
[185]Cochrane W, AfolabiO. Investigation into the nutritional status, dietary in take and smoking habits of patients with chronic obstructive pulmonary disease[J]. J Hum Nutr Diet,2004 Feb; 17(1):3-11.
[186]任立新,杨敬平,刘鹏珍,等.营养支持与呼吸操提高COPD患者生存质的探讨探讨[J].临床肺科杂志,2006,11(3)：331-332.
[187]CaiB, ZhuY. MaY, etal. Efect of Supplementing a high-fat, low carbohydrate enteral formula in COPD patients[J]. Nutrition,2003; 19(3):229-232.
[188]杨勤兵,林江涛.稳定期慢性阻塞性肺疾病患者的营养干预[J].中华全科医师杂志,2003,2(5) ：288-290.
[189]李志平,卢桂芳,黄旭斌,等.缓解期慢性阻塞性肺疾病患者呼吸氦氧混合气后肺活量及其组成的变化[J].中国综合临床,2004,20(2)：134-135.
[190]南登昆.康复医学[M].第2版.北京：人民卫生出版社,2000.
[191]徐少华,王伟,邵红艳,等.超短波治疗对患者诱导痰中炎症细胞及IL-8和TNF-α的影响[J].中华物理医学与康复杂志,2005,27(3)：171-173.
[192]王丽华,方宗君,蒋浩明.30例慢性阻塞性肺疾病患者体外膈肌起搏长程治疗临床观察[J].临床荟萃,1999,14：439-441.
[193]王倩,金荣疆.COPD缓解期的康复治疗国内进展[J].中国康复,2008,23(1)：56-58.
[194]孙瑜霞,毛毅敏,张英民.BiPAP呼吸机在COPD缓解期患者康复治疗中的应用[J].山东医药,2006,46(4)：40-41.
[195]Romagnani s. Biology of human THI and TH2 cells. J Clin Immunol,1995;15(3):121—129
[196]张伟,邵雨萌,张心月.辨证施治经典方剂对慢性阻塞性肺疾病大鼠细因子及Thl/Th2失衡的干预效应.中国组织工程研究与临床康复,2007：11(12)：2363-2367.
[197]张仲景.金匮要略方论[M].北京：中国书店,1993.42.
[198]邹澍.本经疏证[M].上海：上海科学技术出版社,1959.26.
[199]焦红军.党参的药理作用及其临床应用.临床医学,2005,25(4)：92-93
[200]王晓玲,王大果,高国风,等.半夏合剂对模型动物气道分泌物的清除作用研究(J].中国药房,2005,16(10)t740.
[201]李爱华,等.化州产山药的药理作用.1999,22(11)：587.
[202]刘晓晖,朱鳃鹏.许立.等.人参皂甙Rbl的研究进展(J).武警医学院学报,2006,15(1)：82.
[2]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：21.
[3]田代华(整理).灵枢经.北京：人民卫生出版社,2005：75.
[4]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：45.
[5]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：17.
[6]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：87.
[7]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：11.
[8]田代华(整理).灵枢经.北京：人民卫生出版社,2005：134.
[9]秦越人(编撰).难经.北京：科学技术文献出版社,1999：23.
[10]秦越人(编撰).难经.北京：科学技术文献出版社,1999：16.
[11]秦越入(编撰)难经.北京：科学技术文献出版社,1999：22.
[12]秦越人(编撰).难经.北京：科学技术文献出版社,1999：27.
[13]田代华(整理).灵枢经。北京：人民卫生出版社,2005：12.
[14]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：75.
[15]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：114.
[16]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：74.
[17]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：79.
[18]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：49.
[19]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：94.
[20]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：48.
[21]秦越人(编撰)难经.北京：科学技术文献出版社,1999：10.
[22]田代华(整理).黄帝内经素问.北京：人民卫生出版社,200s：183.
[23]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：46.
[24]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：47.
f25]秦越人(编撰1难经.北京：科学技术文献出版社,1999：36.
[26]秦越人(编撰1难经.北京：科学技术文献出版社,1999：7.
[27]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：12.
[28]田代华(整理).黄帝内经素问.北京：人民卫生出版社,200s：13.
[29]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：8.
[30]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：27.
[31]汉·张仲景(撰),何任等(整理)金匿要略.北京：人民卫生出版社,2005：54.
[32]清·唐宗海(著),魏武英等(整理)血证论.北京：人民卫生出版社,2005：139.
[33]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：44.
[34]明·赵以德.金匮方论衍义.北京：中国中医药出版社,1993：106.
[35]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：4.
[36]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：26.
[37]汉.张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：27.
[38]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：28.
[39]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：22.
[40]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：31.
[41]奚肇庆.试论《金匮要略》胸痹与肺的证治.南京中医药大学学报：1995,11(3)：6.
[421汉·张仲景(撰)’何任等(整理).金匮要略.北京：人民卫生出版社,2005：48.
[43]韩春生,张洪春.《金匮要略》肺病诸方探要.国医论坛：1996,11(1)：3.
[441汉·张仲景(撰),何任等(整理).金匮要略.北京：人民卫生出版社,2005：51.
[45]黄树曾.金匮要略释义.北京：人民卫生出版社,1960：166.
[46]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版桂,2005：7.
[47]汉·张仲景(撰),何任等(整理)金匮要略.北京：入民卫生出版社,2005：8.
[48]汉·张仲景(撰),何任等(整理)金匮要咯北京：人民卫生出版社,2005：19.
[49]汉·张仲景(撰)’何任等(整理)金匮要略.北京：人民卫生出版社,2005：21.
[50]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：55.
[51]明·张介宾类经.上海：上海古籍出版社,1997：776-21.
[52]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：62.
[53]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：41.
[54]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：69.
[55]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：42.
[56]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：56.
[57]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：70.
[58]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：78.
[59]清·柯琴(编撰)伤寒来苏集·伤寒论翼.上海：上海科学技术出版社,1,59：27.
[60]明·汪绮石(撰),谭克陶等(整理).理虚元鉴.北京：人民卫生出版社,2005：15.
[61]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：23.
[62]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：29.
[63]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：12.
[64]清·张锡纯.医学衷中参西录.石家庄：河北人民出版社,1974：245.
[65]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：79.
[66]清·尤怡.金匮要略心典.北京：中国中医药出版社,1992：145.
[67]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：83.
[68]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：45.
[69]清·李踅.金匮要略广注.北京：中国中医药出版社,1992：103.
[70]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：86.
[71]汉·张仲景(撰),何任等(整理)金匮要略。北京：人民卫生出版社,2005：46.
[72]清·程杏轩.医述.合肥：安徽科学技术出版社,1990：794.
[73]汉·张仲景(撰),何任等(整理)金匮要略.北京：人民卫生出版社,2005：3.
[74]清·唐宗海.中西汇通医书五种.上海千顷堂书局,1937：156.
[75]清·唐宗海(撰),王咪咪等(主编).唐容川医学全书.北京：中国中医药出版社,1999：209.
[76]清·喻昌(著),徐复霖(点校).医门法律.上海：上海科学技术出版社,1983：269.
[77]清·周岩.本草恩辨录.北京：人民卫生出版社,1963：16.
[78]清·吴谦等(编著),闫志安等(校注).医宗金鉴.北京：中国中医药出版社,1994：6.
[79]清·叶天士(著),潘华信等(主编).叶天士医案大全.上海：上海中医药大学出版社,1994：56.
[80]清·柯琴(编撰).伤寒来苏集·伤寒附翼.上海：上海科学技术出版社,1959： 9.
[81]柴可夫(编著),《金匮要略》理法方药研究,上海：上海中医药大学出版社,2002：190.
[82]清·黄官绣.本革求真.北京：人民卫生出版社,1987：83.
[83]明·李时珍.本草纲目.北京：人民卫生出版社,2004：1008.
[84]魏·吴普等(述),清-孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：92.
[85]魏.吴普等(述),渣·孙星衍,孙冯翼(辑)。神农本草经。北京：科学技术文献出版社,1999：57.
[86]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005：161.
[87]粱·陶弘景(集).名医别录(辑校本)。北京：人民卫生出版社,1986：104.
[88]魏·吴普等(述),清·孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：18.
[89]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005：21.
[90]清·赵学敏.本草纲目拾遗.北京：中国中医药出版社,1998：332.
[91]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 9.
[92]明·李时珍.本草纲目.北京：人民卫生出版社,2004：1268.
[93]魏·吴普等(述),清·孙星衍,孙冯翼(辑).神农本草经.北京：科学技术文献出版社,1999：58.
[94]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 189.
[95]田代华(整理).黄帝内经素问.北京：人民卫生出版社,2005：5.
[96]田代华(整理).灵枢经.北京：人民卫生出版社,2005：96.
[97]清·柯琴(著).伤寒来苏集·伤寒附翼.上海：上海科学技术出版社,1959： 1.
[98]清·张山雷.张山雷医集.北京：人民卫生出版社,1995：234.
[99]汉·张仲景(撰),何任等(整理)金匿要嗡北京：人民卫生出版社,2005：21.
[100]清·张璐.张氏医通。北京：中国中医药出版社,1995：74.
[101]明·李时珍本草纲目.北京：人民卫生出版社,2004：818.
[102]清·汪昂(撰),郑金生(整理).本草备要.北京：人民卫生出版社,2005： 200.
[103]明·李时珍本草纲目.北京：人民卫生出版社,2004：1239。
[104]中华医学会呼吸病学分会.《慢性阻塞性肺疾病诊治指南(2007年修订版)》中华内科杂志,2007,46(3)：254。
[105]Zhong W ang C, Ran P, et a.l Prevalence of chron icob structive pulmonary disease in China:a large, population-based survey[J]. Am J Resp ir CarM ed,2007,176:753-760
[106]HalbertR J, Isonaka S, George D, IqbalA. Interpret ing COPD prevalen ceestimates:what what is the true burden of disease[J] Chest 2003,123:1684-1692.
[107]Preseott E:Vestbo J. Socioeconomic status and chronic obstructv epulmonary disease Thorax,1999,54:737—741.
[108]Anthonisen NR:Connett JE:Murray RP. Smoking and lung function of Lung Health Study participants after 11 years.Am J ResPir Crit Care Med,2002,166:675-679.
[109]冉丕鑫,王辰,姚婉贞,等.我国部分农村地区40岁以上女性慢性阻塞性肺疾病危险因素分析中华内科杂志,2006,45(12)：974-979.
[110]张明泳,刁玉荃.慢性阻塞性肺疾病危险因素的调查.齐鲁医学杂志,2007,22(5)：441-444
[111]Bosse Y. Genetics of chronic obstructive pulmonary disease:a succinct review, future succinct review, future avenues and prospective clinical applications [J]. Pharmacogenomics, 2009; 10(4):655-67.
[112]Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis,2007; 2 (4):541-50.
[113]Rennard SI. COPD:Overview of definitions, Epidemiology and factors influencing its deve lopment. Chest,1998,113:235-241.
[114]Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency[J]. Scand J Clin Lab Invest,1967;19(3):205-8.
[115]Hersh CP, Pillai SG, Zhu G, et al. Multistudy fine mapping of chromosome 2q identifies 2q identifies XRCC5 as a COPD Susceptibility Gene[J]. Am J Respir Crit Care Med,2010; 182(5):605-13.
[116]钱小顺,朱元任,许文兵,等.127例肺部真菌感染的临床分析[J].中华结核和呼吸杂志,2000；23(7)：417-419.
[117]赵玲珑,肖玉艳.慢性阻塞性肺疾病发病因素研究进展[J].广东医学,2006,27(9)：42-43.
[118]程显声,武阳本,李景周等.吸烟者慢性阻塞性肺病易患因素的研究[J].中华结核和呼吸杂志1999；22：602-604.
[119]谢高强,程显声,徐希胜,等.慢性支气管炎患者慢性阻塞性肺疾病发病影响因素的研究.中华医学杂志,2001,81(22)：1356-1359.
[120]王红阳,赵雪峰,李球兵,等COPD及其吸烟患者IL-8、TNF-a、hsCRP的检测及意义.山东医药,2007,47(32)：42-44.
[121]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版).中 华结核和呼吸杂志,2007：30(1)：8-17.
[122]H arik-Khan R I, Fleg J L, W ise R A. Body mass index and the risk of COPD[J]. Chest,2002, 121(2):370-376.
[123]邝锦辉.吸烟与慢性阻塞性肺气肿的发病机理.国外医学呼吸系统分册,2000；20(1)：33-36.
[124]Chaudhuri N, Dower SK, Whyte MK, et al. Toll-like receptors and chnic Lung disease. Clin Sci(Lond),2005:109:125-133.
[125]Turino GM. Emphysema in COPD:consequence and eanses. Th orax.2006; 61:1031.1032.
[126]蔡柏蔷.慢性阻塞性肺部疾病发病机制的新进展.中华内科杂志,2000；39(3)：204-206.
[127]蔡柏蔷.呼吸内科学,北京：中国协和医科大学出版社,2005；5：325-346.
[128]MaestrelliP, Paskae, SaeRa M, et al. Decreased hacm oxygenase-land Inereased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J,2003; 21:971-976.
[129]王晓园,许西琳,刘冬,等.慢性阻塞性肺疾病患者血清Fas/A pol及TNF-a与细胞凋亡的相关性研究.临床肺科杂志2008,13(10)：1294-1295.
[130]王金泉.对慢性阻塞性肺疾病(COPD)的认识[J].中国中医药现代远程教育.2010,82(2)：136.
[131]W alter RE, W ilk JB, Larson MG, et al System ic inflammation and COPD:the Fram ing ham Heart Study [J].Chest,2008,133 (1):19-25.
[132]Pierce R. Spirom etry:an essential clinicalm easurement[J]. Aust Fam Physician,2005, 34(7):535-539.
[133]张利华,王云华COPD肺功能影像学诊断研究进展[J]长治医学院学报,2010,23(3)：237-240.
[134]熊玉干,陈蕾.呼吸肌功能锻炼对老年慢性阻塞性肺疾病患者运动耐力的影响[J].淮海医药,2006,24(6)：514-515.
[135]胥杰孙永昌COPD急性加重的治疗原则[J].临床药物治疗杂志2011,9(6)：45-47.
[136]黄维建COPD急性加重期综合治疗探讨[J].实用心脑肺血管病杂志,2010,18(7)：1012-1013.
[137]白春学.慢性阻塞性肺疾病急性加重期的综合治疗[J].中国临床医学,2003,10(4)：439-441.
[138]蔡柏蔷.科学认识、重视防治、勇于探索—评析国内外慢性阻塞性肺疾病诊断和治疗新指南[J].内科理论与实践,2007,2：287-291.
[139]Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacer bations and airflow in patients with COPD[J]. Eur Respir J,2006; 27 (3):547-55.
[140]Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J]. N Engl J Med,2007; 356(8):775-89.
[141]Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmaco-therapy On rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study[J]. Am J Respir Crit Care Med,2008;178(4):332-8.
[142]Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronicobstructive in chronicobstructive pulmonary disease[J]. N Engl J Med,2008; 359 (15):1543-54.
[143]Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pul-monary disease (UPLIFT):a prespecif ied subgroup subg roup analysis of a randomised controlled clinical trial [J]. Lancet,2009; 374; (9696):1171-8.
[144]Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies [J]. Int J Chron Obstruct Pulmon Dis TORCH and UPLIFT 2009; 4(1):185-201.
[145]LIPWORTH B J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmo ary disease [J].Lancet,2005,365:167-175.
[146]李时珍、许仁勇、陈青妹等.非诺特罗和异丙托澳钱雾化吸入治疗稳定期慢性阻塞性肺病[J].蚌埠医学院学报,2001；26(3)：224-225.
[147]BRUSASCO V, HODDER R, M IRAV ITLLES M, et al.Health outcomes following treatment for six months with once daily tiotrop iura compared with twice daily salm eterol in patients with COPD[J]. Thorax,2003,58:399-404
[148]李周平.慢性阻塞性肺疾病治疗进展[J].实用医院临床杂志2007,1(4)：404-26.
[149]李国平.慢性阻塞性肺疾病治疗进展[J].实用医院临床杂志,2007,1(4)：25-26.
[150]楼英彪、应延风.缓释茶碱对中重度慢性阻塞性肺疾病生存质量影响[J].中华实用中西医杂志,2003：3(16)：1549-1552.
[151]施焕中.慢性阻塞性肺疾病[M].北京：人民卫生出版社,2006：79-84.
[152]周伟雄.普米克令舒和博利康尼联合雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效观察[J].实用临床医学,2006,7(9)：54-55.
[153]Zafarullah M, Li WQ, Sylvester J, et al. Molecular mechanisms of N-acetylcysteine actions [J].Cell Mol Life Sci,2003,60:6-20.
[154]Massaro GD.Massaro D. Retinotic acid treament partially rescues failed septation in rats failed septation in rats and in mice[J]. Am J Physiol Lung Cell Mol Physiol,2000,278:955-960.
[155]Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD[J].Eur Respir J,2006,27(3):547-55.
[156]Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356(8):775-89.
[157]Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmaco-therapy on rate of decline of lung function in chronic obstructive pulmonary disease:results from the TORCH study[J].Am J Respir Crit Care Med,2008; 178(4):332-8.
[158]Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med,2008; 359
[159]Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pul-monary dis ease(UPLIFT):a prespecified subgroup analysis of a randomised contr olled clinical trial[J]. Lancet,2009; 374(9696):1171-8
[160]Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients:less ons from the TORCH and UPLIFT studies [J]. Int J Chron Obstruct Pulmon Dis,2009; 4(1); 185-201.
[161]Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary [J]. Am J Respir Crit Care Med,2007; 176(6):532-55.
[162]丁进,应延风,王永兴.茶碱对中重度慢性阻塞性肺疾病稳定期肺功能和症状的影响[J].现代中西医结合杂志,2004：13(2)：147-8.
[163]Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination the rapy in the treatment of COPD[J]. Chest,2001; 119(6):1661-70.
[164]Cosio BG, Soriano JB. Theophyl line again Reasons for believi[J].2009; 33(5):1010-7.
[165]Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory the anti-inflammatory effects of steroids during exacerbations of COPD[J]. Thorax,2009; 64(5):424-9.
[166]Alifano M, Cuvelier A, Delage A. Treatment of COPD:from pharmao logical to instrumental logical to instrumental therapies[J].Eur Respir Rev,2010; 19(115)-
[167]Kawayama T, Hoshino T, Ichiki M, et al. Effect of add-on therapy of tiotropium in COPD (?)ated with theophylline[J]. Int J Chron Obstruct Pulmon Dis,2008; 3(1):137-47.
[168]Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dexamethasone of cytokine dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease[J]. Am J Respir OritCare Med,2003,167 (1):24-31.
[169]唐继红,顾宗元,王磊,等.皮质激素水平和全身性皮质激素在稳定期慢性阻塞性肺疾病中的应用[J].中华现代内科学杂志,2007,32(4)：389-391.
[170]Zheng JP, Kang J, Huang SG, et al. Effect of Carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a ran-domised placebo-controlled study J). Lancet,2008; 371
[171]陆再英,钟南山.内科学[M].北京：人民卫生出版社,2008：132-138
[172]Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD;a randomized placebo-controlled randomized placebo-controlled study (J).Chest,2009; 136(2):381-6.
[173]Campos M A, Wanner A. The rationale for pharmacologic therapy in stable chronic obstructivepulmonary disease[J]. Am J Med Sci,2005,329(4):181-189.
[174]陈新谦,金有豫,汤光.新编药物学[M].16版.北京：人民卫生出社,2007：213-219.
[175]马国尔,郑金旭.中性粒细胞弹性蛋白酶抑制剂研究现状[J].国际呼吸杂志,2006,26(4)：257-259.
[176]谭群友,龚太乾,王如文,蒋耀光.慢性阻塞性肺疾病的外科进展[J]临床外科杂志,2004：12(5)：310.
[177]0ey IF;Morgan MD; Singh SJ. The long term health status improv ements seen after lung volume reduetion surgery[J]. Eur J Cardiothorac Surg;2003;24 (4):6142619.
[178]刘锦铭,杨文兰,姜格宁；等.肺移植对5例慢性阻塞性肺疾病患者肺功能的影响.中华结核和呼吸吸杂志；2005,28(8)：509-512.
[179]Global Strategy for the Diagnosis, Management, and Preventionof Chronic obstruetive Pulmonary Disease(2006).2006 Global Initative for Chronic obstruetive Lung Disease.
[180]杨悦,许少华.78例重度COPD患者对COPD的认知及治疗现状[J].医学临床研究,2006,23(6)
[181]Geddes EL, ReidWD, Crowe J, et a 1. Inspiratory muscle training in adults with obstruc tive pulm on ary disease an update of a system at ic review[J]. RespirMed,2005,99(11): 1140-1158.
[182]Alneriean thoracic soeiety. Pulmonary rehabilitation,1999. Am J ResPir Crit Care Med, 1999; 159:1666-1682.
[183]黎东明,林志雄.慢性阻塞性肺疾病患者心理状况及影响因素分析[J].海预防医学杂志,2005,17(1)：5-7.
[184]Houghton L. Thenutritional man agement of weight loss in COPD[J]. Best Practice, 2008(15),16-17.
[185]Cochrane W, AfolabiO. Investigation into the nutritional status, dietary in take and smoking habits of patients with chronic obstructive pulmonary disease[J]. J Hum Nutr Diet,2004 Feb; 17(1):3-11.
[186]任立新,杨敬平,刘鹏珍,等.营养支持与呼吸操提高COPD患者生存质的探讨探讨[J].临床肺科杂志,2006,11(3)：331-332.
[187]CaiB, ZhuY. MaY, etal. Efect of Supplementing a high-fat, low carbohydrate enteral formula in COPD patients[J]. Nutrition,2003; 19(3):229-232.
[188]杨勤兵,林江涛.稳定期慢性阻塞性肺疾病患者的营养干预[J].中华全科医师杂志,2003,2(5) ：288-290.
[189]李志平,卢桂芳,黄旭斌,等.缓解期慢性阻塞性肺疾病患者呼吸氦氧混合气后肺活量及其组成的变化[J].中国综合临床,2004,20(2)：134-135.
[190]南登昆.康复医学[M].第2版.北京：人民卫生出版社,2000.
[191]徐少华,王伟,邵红艳,等.超短波治疗对患者诱导痰中炎症细胞及IL-8和TNF-α的影响[J].中华物理医学与康复杂志,2005,27(3)：171-173.
[192]王丽华,方宗君,蒋浩明.30例慢性阻塞性肺疾病患者体外膈肌起搏长程治疗临床观察[J].临床荟萃,1999,14：439-441.
[193]王倩,金荣疆.COPD缓解期的康复治疗国内进展[J].中国康复,2008,23(1)：56-58.
[194]孙瑜霞,毛毅敏,张英民.BiPAP呼吸机在COPD缓解期患者康复治疗中的应用[J].山东医药,2006,46(4)：40-41.
[195]Romagnani s. Biology of human THI and TH2 cells. J Clin Immunol,1995;15(3):121—129
[196]张伟,邵雨萌,张心月.辨证施治经典方剂对慢性阻塞性肺疾病大鼠细因子及Thl/Th2失衡的干预效应.中国组织工程研究与临床康复,2007：11(12)：2363-2367.
[197]张仲景.金匮要略方论[M].北京：中国书店,1993.42.
[198]邹澍.本经疏证[M].上海：上海科学技术出版社,1959.26.
[199]焦红军.党参的药理作用及其临床应用.临床医学,2005,25(4)：92-93
[200]王晓玲,王大果,高国风,等.半夏合剂对模型动物气道分泌物的清除作用研究(J].中国药房,2005,16(10)t740.
[201]李爱华,等.化州产山药的药理作用.1999,22(11)：587.
[202]刘晓晖,朱鳃鹏.许立.等.人参皂甙Rbl的研究进展(J).武警医学院学报,2006,15(1)：82.